A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation (PRESBUS)
Status
Conditions
Details and patient eligibility
About
The purpose of this study is to provide real-world data useful to address the factors associated to the administration of oral anticoagulants in the elderly population affected by non-valvular atrial fibrillation (NVAF), in Italy, and it's persistence rate after one year.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Diagnosis of any type (e.g. persistent, permanent, paroxysmal) of Non-Valvular Atrial Fibrillation (NVAF) documented in the participant's medical chart based on electrocardiogram (ECG) results, or diagnosed at enrollment
- Naïve to anticoagulant treatments, or not having received anticoagulant treatments during the 6 months prior to enrollment
- Multidimensional geriatric assessment (MGA) performed at enrollment, or anyway no more than 3 months before in case of stable disease (i.e. no relevant events) in the previous 3 months
Exclusion Criteria:
- Valvular atrial fibrillation (AF) due to artificial heart valve
- Medical conditions (apart from NVAF) requiring anticoagulant therapy (such as deep vein thrombosis or pulmonary embolism)
- Use of inappropriate direct-acting oral anticoagulant (DOAC) doses based on the current summary of product characteristics (SmPC) for any drugs
Trial design
720 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,; First line of the email MUST contain NCT # and Site #.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal